CREDIT RISK UPDATESChemicals - Specialty

Tatva Chintan Pharma Chem Limited sees a credit rating action

Tatva Chintan Pharma Chem LimitedTATVA

TL;DR

CRISIL did not disclose specific debt-to-EBITDA or interest-coverage improvements in the rating notification. The filing records the upgrade of long-term ratings from CRISIL BBB+/Stable to CRISIL A-/Stable and short-term ratings from CRISIL A2 to CRISIL A2+ on bank facilities of Rs 245 Crores, but it does not provide the previous-cycle or current-cycle leverage and coverage figures, nor does it identify those metrics as the primary drivers.

What specific improvements in Tatva Chintan’s financial risk profile—such as debt-to-EBITDA ratios or interest coverage metrics—did CRISIL cite as the primary drivers for this rating upgrade compared to the previous rating cycle?

CRISIL did not disclose specific debt-to-EBITDA or interest-coverage improvements in the rating notification. The filing records the upgrade of long-term ratings from CRISIL BBB+/Stable to CRISIL A-/Stable and short-term ratings from CRISIL A2 to CRISIL A2+ on bank facilities of Rs 245 Crores, but it does not provide the previous-cycle or current-cycle leverage and coverage figures, nor does it identify those metrics as the primary drivers. [1]

The available financial metrics give a mixed picture rather than a clean deleveraging story:

  • Consolidated interest coverage improved from 6.88x in FY25 to 21.00x in FY26, an increase of 14.12x, indicating materially stronger earnings capacity relative to finance costs. [2]
  • Consolidated net debt-to-EBITDA, however, increased from 0.68x to 1.19x over the same period—an increase of 0.51x, which is a deterioration in leverage, not an improvement. [3]
  • In Q1 FY27, consolidated net debt-to-EBITDA was 3.27x and interest coverage was 16.87x, so the latest quarterly snapshot does not establish a further improvement in leverage or coverage versus FY26. [3] [2]

Analytical conclusion: the only clearly improved reported credit metric is interest coverage through FY26; the available leverage data moved in the opposite direction. Accordingly, it would be incorrect to attribute the upgrade specifically to a lower debt-to-EBITDA ratio or to claim that CRISIL cited a quantified improvement in either metric. The detailed CRISIL rationale or rating rationale document would be required to identify the actual primary drivers.

Given the specialty chemicals sector's recent working capital pressures, how does this upgrade reflect changes in Tatva Chintan’s liquidity position and reliance on short-term debt compared to the previous fiscal year's reported debt structure?

The upgrade reflects better assessed credit access and repayment capacity, not an improvement in balance-sheet liquidity. Tatva Chintan’s FY26 numbers show a materially weaker liquidity cushion and much greater absolute reliance on short-term borrowings than in FY25, even though a small portion of debt shifted into non-current borrowing.

The working-capital signal is also mixed: inventories rose from Rs 133.95 Crores to Rs 196.07 Crores and inventory days increased from 263.0 to 268.2 days, while trade receivables increased from Rs 82.53 Crores to Rs 119.03 Crores with receivable days unchanged at 72.7 days [17] [18] [19] [20]. Operating cash flow coverage weakened, with OCF-to-debt declining from 0.68x to 0.26x, and cash conversion falling from 67.5% to 32.6% [21] [22].

Against this backdrop, Crisil upgraded the long-term rating to A-/Stable from BBB+/Stable and the short-term rating to A2+ from A2 on rated bank facilities of Rs 245 Crores [23]. The implication is that the upgrade likely improves lender confidence and financing access, but it should not be read as evidence that short-term debt dependence has reduced. The debt mix became marginally more term-oriented, yet FY26 funding remained overwhelmingly current, while lower cash and a weaker current ratio point to greater liquidity sensitivity. The rating upgrade therefore appears to reflect credit-quality or access considerations that offset the weaker reported liquidity metrics; the rating article does not disclose the precise quantitative drivers behind Crisil’s decision.

Consolidated metricFY25FY26Change and interpretation
Current ratio2.76x [10]1.64x [10]Down 1.12x; liquidity headroom narrowed
Cash and equivalentsRs 11.37 Crores [11]Rs 5.76 Crores [11]Down 49.30%; lower immediate cash buffer
Current borrowingsRs 36.39 Crores [12]Rs 115.36 Crores [12]Up 217.00%; substantially higher short-term funding
Non-current borrowingsNil [13]Rs 5.01 Crores [13]Limited term-debt addition
Total debtRs 36.39 Crores [14]Rs 120.37 Crores [14]Up approximately 230.75%
Short-term borrowings as % of total debt100.00%, derived [12] [14]95.84%, derived [12] [14]Mix improved marginally, but absolute short-term debt increased sharply
Current liabilitiesRs 96.03 Crores [15]Rs 213.13 Crores [15]Up 121.90%, faster than current assets
Current assetsRs 265.25 Crores [16]Rs 349.51 Crores [16]Up 31.80%

Sources

  1. [1]Tatva Chintan Pharma Chem Limited Announces Credit Rating Upgrade by CRISIL — 2026-09-08T17:16:53, p.1
  2. [2]Interest Coverage Ratio
  3. [3]Net Debt to EBITDA
  4. [4]Latest Current Borrowings
  5. [5]Latest Non-Current Borrowings
  6. [6]Latest Total Debt
  7. [7]Tatva Chintan Pharma Chem Limited Announces Credit Rating Upgrade by CRISIL — 2026-09-08T17:16:53, p.2
  8. [8]Tatva Chintan Pharma Chem Limited Announces Credit Rating Upgrade by CRISIL — 2026-09-08T17:16:53, p.3
  9. [9]Tatva Chintan Pharma Chem Ltd Management Discussions — Indiainfoline, 2026-09-08T16:02:11.529346
  10. [10]Current Ratio
  11. [11]Cash and Equivalents
  12. [12]Current Borrowings
  13. [13]Non-Current Borrowings
  14. [14]Total Debt
  15. [15]Current Liabilities
  16. [16]Current Assets
  17. [17]Inventories
  18. [18]Inventory Days
  19. [19]Trade Receivables
  20. [20]Receivable Days
  21. [21]TTM OCF to Debt
  22. [22]TTM Cash Conversion
  23. [23]Crisil Upgrades Tatva Chintan's Credit Ratings on Rs.245 ... — Tipranks, 2026-09-08T16:03:22.360454

Keep digging

What specific improvements in Tatva Chintan’s financial risk profile—such as debt-to-EBITDA ratios or interest coverage metrics—did CRISIL cite as the primary drivers for this rating upgrade compared to the previous rating cycle?

Ask Copilot
Logo

Unlock financial AI for your firm

Log in